Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the firm’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $48.85, for a total value of $732,750.00. Following the completion of the sale, the chief executive officer now directly owns 1,309,487 shares of the company’s stock, valued at $63,968,439.95. This represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.58, for a total value of $698,700.00.
• On Wednesday, November 6th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00.

Apogee Therapeutics Stock Performance

Apogee Therapeutics stock opened at $41.05 on Friday. Apogee Therapeutics, Inc. has a fifty-two week low of $30.84 and a fifty-two week high of $72.29. The stock has a market cap of $1.85 billion, a P/E ratio of -16.96 and a beta of 2.26. The firm’s fifty day moving average price is $48.43 and its 200-day moving average price is $49.00.

Hedge Funds Weigh In On Apogee Therapeutics

A number of institutional investors have recently added to or reduced their stakes in APGE. JPMorgan Chase & Co. grew its holdings in shares of Apogee Therapeutics by 4.3% during the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,212 shares in the last quarter. Geode Capital Management LLC grew its stake in Apogee Therapeutics by 11.2% in the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock worth $48,401,000 after buying an additional 82,978 shares in the last quarter. Barclays PLC increased its holdings in shares of Apogee Therapeutics by 369.2% in the 3rd quarter. Barclays PLC now owns 365,046 shares of the company’s stock worth $21,443,000 after buying an additional 287,243 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Apogee Therapeutics by 35.7% during the 3rd quarter. Wellington Management Group LLP now owns 4,814,400 shares of the company’s stock valued at $282,798,000 after buying an additional 1,267,451 shares in the last quarter. Finally, Wexford Capital LP bought a new stake in shares of Apogee Therapeutics during the 3rd quarter worth $230,000. 79.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

APGE has been the topic of a number of recent research reports. Wedbush upped their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, December 2nd. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price target for the company. Finally, Canaccord Genuity Group started coverage on Apogee Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $89.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.71.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.